Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philidor Rx Services

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Valeant uncouples Dendreon and skincare brands to cut debt

Agrees deals worth $2.1bn with L’Oreal and Sanpower Group

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

- PMLiVE

Valeant’s ex-CEO and CFO ‘could face criminal charges’

Sources suggest probe may relate to the company’s former relationship with Philidor Rx Services

- PMLiVE

EpiDemic

Getting serious about drug pricing

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

LEO Pharma picks up AZ skin disease drugs in $1bn deal

Gains rights to eczema and psoriasis treatments

NewLink

NewLink pancreatic cancer vaccine flunks phase III test

Survival rate slightly lower for patients on vaccine than those in control group

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

- PMLiVE

Valeant appoints Joseph Papa to end CEO uncertainty

He will take over from Michael Pearson at the troubled pharma company in May

- PMLiVE

Valeant begins search for new CEO

Michael Pearson will continue in the role until his successor is appointed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links